Cell Signaling Technology Announces Continued Collaboration with AstraZeneca to Provide CST's PhosphoScan Platform for Kinase Inhibitor Proteomic Profiling
"AstraZeneca, having many kinase inhibitor programs for cancer therapy, has been a great partner for CST. We aim to provide AstraZeneca with valuable information based on PhosphoScan(R) discovery and then translate that information into biomarker assays with our proprietary antibody technology," said Christopher Bunker, CST's Director of Business Development. Dr. Bunker added, "CST has enabled AstraZeneca to tap into the wealth of PhosphoScan(R) profiles that we have generated in our internal cancer research; our cancer cell PhosphoSignatures(TM) are enabling our partners to design well informed PhosphoScan(R) studies of their lead compounds, as well as adding to the validation of phospho-epitopes for biomarker assays."
About Cell Signaling Technology, Inc.
Cell Signaling Technology, Inc. has expertise and the market leadership position in the development and commercialization of phospho-specific antibodies and assays for kinase and pathway analysis. CST's phospho-specific antibodies are validated in multiple assay platforms and are critical reagents in all stages of pharmaceutical drug discovery and development.
PhosphoScan(R) profiling leverages CST's core capability in kinase research biology and antibody development, and it is a strategy by which to discover cellular phosphorylation profiles that may enable more efficient and informative kinase drug development. CST is commercializing the PhosphoScan(R) technology through research alliances and contract service. Information on CST can be obtained at the Company's website at www.cellsignal.com.
Cell Signaling Technology, Inc.
Christopher Bunker, Ph.D., 978-867-2307
Director, Business Development
Posted: February 2008